Triple Drug Combo Eradicates 50% More Tumors In HER2-Positive Breast Cancer Than Stan

[News]

Findings of the phase 2 NeoSphere study, published Online First in The Lancet Oncology shows that by adding monoclonal antibody pertuzumab to standard therapy (trastuzumab [Herceptin] plus the chemotherapy drug docetaxel) for women with an aggressive type of early-stage breast cancer (HER2-positive disease) improved the rate of complete tumor disappearance by over half after just four cycles, i.e...

More... (http://www.medicalnewstoday.com/articles/238818.php)